Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
32.02
+0.36 (1.14%)
At close: Sep 30, 2026, 4:00 PM EDT
33.00
+0.98 (3.06%)
After-hours: Sep 30, 2026, 7:58 PM EDT
Cogent Biosciences Employees
Cogent Biosciences had 258 employees as of December 31, 2025. The number of employees increased by 53 or 25.85% compared to the previous year.
Employees
258
Change (1Y)
53
Growth (1Y)
25.85%
Revenue / Employee
n/a
Profits / Employee
-$1,461,934
Market Cap
5.56B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 258 | 53 | 25.85% |
| Dec 31, 2024 | 205 | 41 | 25.00% |
| Dec 31, 2023 | 164 | 26 | 18.84% |
| Dec 31, 2022 | 138 | 61 | 79.22% |
| Sep 30, 2022 | 121 | 44 | 57.14% |
| Dec 31, 2021 | 77 | 62 | 413.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Iovance Biotherapeutics | 975 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 433 |
| CRISPR Therapeutics AG | 393 |
| Scholar Rock Holding | 289 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
COGT News
- 15 days ago - Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application - TheFly
- 15 days ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) - GlobeNewsWire
- 21 days ago - Cogent Biosciences added to Analyst Focus List at JPMorgan - TheFly
- 6 weeks ago - Cogent Biosciences price target raised to $55 from $52 at Piper Sandler - TheFly
- 6 weeks ago - Cogent Biosciences price target raised to $52 from $45 at Guggenheim - TheFly
- 7 weeks ago - Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences Earnings release: Q2 2026 - Filings
- 7 weeks ago - Cogent Biosciences Quarterly report: Q2 2026 - Filings